(HealthDay News) — Among cancer survivors, excess body weight is associated with an increased risk of a second primary cancer, according to a study published in JAMA Network Open.

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...

The FDA has approved Keytruda (pembrolizumab) in combination with chemotherapy as first-line treatment for adults with malignant pleural mesothelioma.

Moderately hypofractionated nodal radiotherapy is not inferior to normofractionated radiotherapy for early breast cancer, data suggest.

Nivolumab plus ipilimumab can provide long-term benefits to patients with advanced melanoma, according to a 10-year update of the CheckMate 067 trial.

Virtual palliative care has similar effects on quality of life as in-person care for patients with advanced non-small cell lung cancer.

Source: Getty Images 177Lu-PNT2002 produced more responses and improved both radiographic and biochemical progression-free survival. The median radiographic progression-free survival was 9.5 months ...

Our easy-to-read fact sheets provide clinicians with reliable information to share with patients and their caregivers. Breast cancer is the most common cancer in women in the United States.